Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

MK-6194 is under clinical development by Merck and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs for Vitiligo have a 42% phase transition success rate (PTSR) indication ...

BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 72% phase ...

BCD-245 is under clinical development by Biocad and currently in Phase I for Ewing Sarcoma. According to GlobalData, Phase I drugs for Ewing Sarcoma does not have sufficient historical data to build ...

Fab’entech (Fabentech) specializes in the development and production of emergency treatments aimed at combating the risks associated with bioterrorism and emerging infectious diseases that are ...

STK-012 is under clinical development by Synthekine and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success ...

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate ...

LXE-408 is under clinical development by Novartis and currently in Phase I for Chagas Disease (American Trypanosomiasis).

CT-7439 is under development for the treatment of solid tumors including breast cancer, ovarian cancer and Ewing's Sarcoma. It acts by targeting cyclin dependent kinase 12 and 13 (CDK12 and 13). It is ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

Tebapivat is under clinical development by Agios Pharmaceuticals and currently in Phase I for Sickle Cell Disease.